CN113880827A - Compound for inhibiting KRASG12C mutant protein and preparation method and application thereof - Google Patents
Compound for inhibiting KRASG12C mutant protein and preparation method and application thereof Download PDFInfo
- Publication number
- CN113880827A CN113880827A CN202010636659.1A CN202010636659A CN113880827A CN 113880827 A CN113880827 A CN 113880827A CN 202010636659 A CN202010636659 A CN 202010636659A CN 113880827 A CN113880827 A CN 113880827A
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- pharmaceutically acceptable
- acceptable salts
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 114
- 108010021466 Mutant Proteins Proteins 0.000 title claims description 5
- 102000008300 Mutant Proteins Human genes 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 10
- 230000002401 inhibitory effect Effects 0.000 title description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 206010004593 Bile duct cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 6
- 201000007983 brain glioma Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102200006538 rs121913530 Human genes 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 102100030708 GTPase KRas Human genes 0.000 description 9
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- -1 piperazine compound Chemical class 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 102000016914 ras Proteins Human genes 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- NBKZGRPRTQELKX-UHFFFAOYSA-N (2-methylpropan-2-yl)oxymethanone Chemical compound CC(C)(C)O[C]=O NBKZGRPRTQELKX-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IPFOCHMOYUMURK-UHFFFAOYSA-N 1-[3-[4-[2-[4-chloro-2-hydroxy-5-(1-methylcyclopropyl)anilino]acetyl]piperazin-1-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C=1C(NCC(=O)N2CCN(CC2)C2CN(C2)C(=O)C=C)=C(O)C=C(Cl)C=1C1(C)CC1 IPFOCHMOYUMURK-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108010027920 GTPase-Activating Proteins Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 239000012094 cell viability reagent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound represented by the following formula (I) and an isomer or pharmaceutically acceptable salt thereof. The compounds may be used to inhibit the KRASG12C mutein and to treat related cancers.
Description
Technical Field
The invention relates to the field of drug synthesis, in particular to a compound for inhibiting KRASG12C mutant protein, and a preparation method and application thereof.
Background
RAS mutations are often observed in malignancies and support a variety of markers of cancer, including genomic instability, cell proliferation, inhibition of apoptosis, reprogramming of metabolism, alteration of the microenvironment, escape of immune response and promotion of metastasis. Consistent with its general effect on cancer cell function, regression of oncogenic KRAS in many established tumor models results in tumor regression. Therefore, RAS is a potentially very effective cancer therapeutic target. RAS mutations appear to have multiple functional classes, and strategies may need to be developed for each functional class.
Among RAS family members, oncogenic mutations are most common in KRAS (85%), whereas NRAS (12%) and HRAS (3%) are less common. Most RAS family mutations occur at amino acid residues 12, 13 and 61, which are mostly direct interactions with GTP in three-dimensional conformations. For example, mutation of glycine at amino acid residue 12 to any other amino acid other than proline creates a steric block that prevents the GAP protein from entering KRAS, thereby inhibiting GTP hydrolysis and resulting in a significant increase in KRAS in the highly active GTP-bound form.
Variant KRAS accounted for 30% of lung cancer. 97% of KRAS variations occur in exons 2 and 3, including amino acids G12 (39%), G13 and Q61. KRAS G12C is the most common RAS mutation in non-small cell lung cancer, the leading cause of cancer death in the united states, and there is still no direct and effective drug clinically. But in recent years there has been significant progress in this area.
In 2013, Shokat et al reported breakthrough results in Nature, who screened active small molecules designed to bind irreversibly to mutant cysteine at G12C in a small pocket near the KRAS effector domain. Small molecules that bind to this pocket can inhibit KRAS activity by locking the protein in a GDP-bound inactive state.
In 2016, Wellspring corporation reported on cancer discovery targeting KRAS G12C small molecule inhibitor ARS-853. Although the activity is still in micromolar, the proof of concept of the cell and animal experiments is completed. In 2018, the company discloses a new generation of targeting KRAS G12C small molecule inhibitor ARS-1620 on cell.
Inhibition of KRAS muteins inhibits the growth of cancer cells, and thus, treatment of cancers such as lung cancer, pancreatic cancer, and colorectal cancer would seem to be a promising therapeutic approach. Thus, there is a potentially great unmet medical need in this field.
WO2015054572 discloses compounds of the following general formula and compound a as a comparison in the present invention, but does not disclose any examples of compounds identical or similar to the present invention.
WO2020081282 discloses compounds of the general formula and compound B as a comparison in the present invention, as well as none of the examples disclose the same compounds as in the present invention.
Compared with the compound A disclosed by WO2015054572 and the compound B disclosed by WO2020081282, the substituted piperazine compound unexpectedly and greatly improves the biological activity, improves the metabolic stability, shows good pharmacokinetic properties and has better druggability. Meanwhile, when the F substituent of R2 on the ring is replaced by amino in the above formula, the good biological activity is also unexpectedly maintained.
Disclosure of Invention
In order to solve the technical problems, the invention adopts the following technical scheme:
according to one aspect of the present invention, there is provided a compound represented by the following formula (I) and isomers thereof or pharmaceutically acceptable salts thereof,
wherein the content of the first and second substances,
R1is selected from-H, -CH3、-CH2CN;
R2Is selected from-H, -CH3;
R3Is selected from-H, -CH3;
R4Selected from-F, -NH2、-NHCH3;
When R is4When is-F, said R1、R2、R3Cannot be simultaneously-H.
According to another aspect of the present invention, preferably, in the structure represented by formula (I), R1is-CH2CN;R2is-H; r3is-H; r4Selected from-F, -NH2。
According to another aspect of the present invention, preferably, in the structure represented by formula (I), R1is-H; r2is-CH3;R3is-H; r4Selected from-F, -NH2。
According to another aspect of the present invention, preferably, in the structure represented by formula (I), R1is-H; r2is-CH3;R3is-CH3;R4Selected from-F, -NH2。
According to another aspect of the present invention, preferably, in the structure represented by formula (I), R1is-CH3;R2is-H; r3is-H; r4Selected from-F, -NH2。
Even more preferably, R4is-F.
Still more preferably, the compound represented by formula (I) and isomers thereof or pharmaceutically acceptable salts thereof are selected from the following compounds:
according to another aspect of the invention, the invention provides a compound represented by formula (I) and pharmaceutically acceptable salts thereof and isomers thereof or pharmaceutically acceptable salts thereof for use in the preparation of a medicament for treating a KRASG12C mutein-related cancer.
Preferably, according to said use, said KRASG12C mutein-related cancer disease is selected from the group consisting of: lung cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, esophageal cancer, bile duct cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, brain glioma, lymphoma, and leukemia.
According to another aspect of the present invention, the present invention provides a pharmaceutical composition for treating KRASG12C mutein related cancers, comprising a therapeutically effective amount of a compound represented by formula (I) and pharmaceutically acceptable salts thereof and isomers thereof or pharmaceutically acceptable salts thereof according to the present invention as an active ingredient, and pharmaceutically acceptable excipients.
Preferably, according to the pharmaceutical composition, the KRASG12C mutein-related cancer disease is selected from the group consisting of: lung cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, esophageal cancer, bile duct cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, brain glioma, lymphoma, and leukemia.
According to another aspect of the present invention, the present invention provides a method for treating KRASG12C mutein-related cancer, comprising administering to a subject an effective amount of the compound according to the present invention or a pharmaceutical composition comprising the compound and pharmaceutically acceptable salts thereof as an active ingredient.
Preferably, according to said method of treatment, said KRASG12C mutein related cancer is a treatment of a cancer disease selected from the group consisting of: lung cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, esophageal cancer, bile duct cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, brain glioma, lymphoma, and leukemia.
Detailed Description
Hereinafter, the present invention will be described in detail. Before the description is made, it should be understood that the terms used in the present specification and the appended claims should not be construed as limited to general and dictionary meanings, but interpreted based on the meanings and concepts corresponding to technical aspects of the present invention on the basis of the principle that the inventor is allowed to define terms appropriately for the best explanation. Accordingly, the description proposed herein is just a preferable example for the purpose of illustrations only, not intended to limit the scope of the invention, so it should be understood that other equivalents and modifications could be made thereto without departing from the spirit and scope of the invention.
In accordance with the present invention, all terms referred to herein have the same meaning as those skilled in the art to understand the present invention, unless otherwise specified.
The term "salt" as used herein refers to a cation and anion containing compound that can be produced by protonation of an acceptable proton site and/or deprotonation of an available proton site. Notably, protonation of the acceptable proton sites results in the formation of cationic species whose charge is balanced by the presence of physiological anions, while deprotonation of the available proton sites results in the formation of anionic species whose charge is balanced by the presence of physiological cations.
The term "pharmaceutically acceptable salt" means that the salt is pharmaceutically acceptable. Examples of pharmaceutically acceptable salts include, but are not limited to: (1) acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as glycolic acid, pyruvic acid, lactic acid, malonic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, 3- (4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1, 2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-p-toluenesulfonic acid, camphoric acid, dodecylsulfuric acid, gluconic acid, glutamic acid, salicylic acid, cis-hexadiene diacid, and the like; or (2) a base addition salt, and a conjugate base of any of the above inorganic acids, wherein the conjugate base comprises a compound selected from Na+、K+、Mg2+、Ca2+、NHxR4-x +The cationic component of (1), wherein NHxR4-x +(R is C1-4Alkyl, subscript x is an integer selected from 0, 1,2, 3, or 4) represents a cation in the quaternary ammonium salt. It is to be understood that all references to pharmaceutically acceptable salts include the solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein of the same acid addition salt.
The term "C1-MAlkyl "refers to an alkyl group containing from 1 to M carbon atoms, for example where M is an integer having the following value: 2. 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. For example, the term "C1-6Alkyl "refers to an alkyl group containing 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, lower alkyl groups including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butylOr pentyl, isopentyl, neopentyl, hexyl, heptyl and octyl.
The term "aryl" refers to an aromatic system that may be a single ring or multiple aromatic rings that are otherwise fused or linked together such that at least a portion of the fused or linked rings form a conjugated aromatic system. Aryl groups include, but are not limited to: phenyl, naphthyl, tetrahydronaphthyl. Aryl groups may be optionally substituted, such as aryl or heterocyclic which may be substituted with 1 to 4 groups selected from: halogen, -CN, -OH, -NO2Amino, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkoxy, alkylcarbonyl, alkylcarboxy, alkylamino or arylthio.
The term "substituted" means that the reference group may be substituted with one or more additional groups individually and independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic hydrocarbon, hydroxy, alkoxy, alkylthio, arylthio, alkylsulfinyl, arylsulfonyl, alkylsulfonyl, arylsulfonyl, cyano, halo, carbonyl, thiocarbonyl, nitro, haloalkyl, fluoroalkyl and amino, including mono-and di-substituted amino groups and protected derivatives thereof.
The compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound provided by the present invention may be in various forms such as tablets, capsules, powders, syrups, solutions, suspensions, aerosols, and the like, and may be present in a suitable solid or liquid carrier or diluent, as well as in a suitable sterile device for injection or instillation.
Various dosage forms of the pharmaceutical composition of the present invention can be prepared according to conventional preparation methods in the pharmaceutical field. For example, a unit dose of the formulation thereof may contain from 0.05 to 200mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, preferably a unit dose of the formulation may contain from 0.1mg to 100mg of a compound of formula (I).
The compounds and pharmaceutical compositions of the present invention represented by general formula (I) can be administered to mammals clinically, including humans and animals, via oral, nasal, dermal, pulmonary, or gastrointestinal routes of administration. Most preferably oral. The optimal daily dosage is 0.01-200mg/kg body weight, and can be administered in one time or 0.01-100mg/kg body weight in several times. Regardless of the method of administration, the optimal dosage for an individual will depend on the particular treatment. Usually starting with a small dose and gradually increasing the dose until the most suitable dose is found.
In the present invention, the term "effective amount" may refer to an effective amount in a dosage and for a period of time required to achieve a desired effect. This effective amount may vary depending on factors such as the type of disease or the condition of the disease being treated, the particular target organ being administered, the size of the individual patient, or the severity of the disease or symptoms. One of ordinary skill in the art can empirically determine the effective amount of a particular compound without undue experimentation.
Typical formulations are prepared by mixing a compound of the invention of formula (I) with a carrier, diluent or excipient. Suitable carriers, diluents or excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble and/or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water and the like.
The particular carrier, diluent or excipient employed will depend upon the mode of use and the purpose of the compound of the invention. The solvent is generally selected based on the solvent that one of skill in the art would consider safe and effective for administration to mammals. Generally, safe solvents are non-toxic aqueous solvents such as water, as well as other non-toxic solvents that are soluble or miscible with water. Suitable aqueous solvents include one or more of water, ethanol, propylene glycol, polyethylene glycol (e.g., PEG400, PEG300), and the like. The formulation may also include one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, glidants, processing aids, colorants, sweeteners, flavoring agents or other known additives to make or use the drug in an acceptable form.
When the compound of formula (I) according to the present invention is used in combination with at least one other drug, the two drugs or more may be used separately or in combination, preferably in the form of a pharmaceutical composition. The compounds or pharmaceutical compositions of the invention according to formula (I) can be administered to a subject separately or together in any known oral, intravenous, rectal, vaginal, transdermal, other topical or systemic administration form.
These pharmaceutical compositions may also contain one or more buffering agents, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifying agents, suspending agents, preservatives, antioxidants, opacifiers, glidants, processing aids, colorants, sweeteners, flavoring agents or other known additives to allow the pharmaceutical composition to be manufactured or used in an acceptable form.
The route of oral administration is preferred for the medicaments of the invention. Solid dosage forms for oral administration may include capsules, tablets, powders or granules. In solid dosage forms, the compounds or pharmaceutical compositions of the present invention are mixed with at least one inert excipient, diluent or carrier. Suitable excipients, diluents or carriers include substances such as sodium citrate or dicalcium phosphate, or starches, lactose, sucrose, mannitol, silicic acid and the like; binders such as carboxymethyl cellulose, alginate, gelatin, polyvinyl pyrrolidone, sucrose, gum arabic, etc.; humectants such as glycerin, etc.; disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, specific complex silicate, sodium carbonate, etc.; solution retarding agents such as paraffin, etc.; absorption accelerators such as quaternary ammonium compounds and the like; adsorbents such as kaolin, bentonite, etc.; lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and the like. In the case of capsules and tablets, the dosage form may also include buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using lactose and high molecular weight polyethylene glycols and the like as excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the compounds of the present invention or pharmaceutical compositions thereof, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents; solubilizers and emulsifiers such as ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylene glycol, dimethylformamide; oils (e.g., cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, etc.); glycerol; tetrahydrofurfuryl alcohol; fatty acid esters of polyethylene glycol and sorbitan; or mixtures of several of these substances, and the like.
In addition to these inert diluents, the compositions can also include excipients such as one or more of wetting agents, emulsifying agents, suspending agents, sweetening, flavoring, and perfuming agents.
The suspension may further contain a carrier such as a suspending agent, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, or a mixture of several of these substances, in addition to the compound represented by the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same.
The compound represented by the general formula (I) or the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the same can be administered by other topical administration dosage forms, including ointments, powders, sprays and inhalants. The medicament may be mixed under sterile conditions with a pharmaceutically acceptable excipient, diluent or carrier, and any preservatives, buffers or propellants which may be required. Ophthalmic formulations, ophthalmic ointments, powders and solutions are also intended to be within the scope of the present invention.
In addition, kits (e.g., pharmaceutical packages) are also contemplated by the present disclosure. The provided kits can comprise a pharmaceutical composition or compound described herein and a container (e.g., a vial, ampoule, bottle, syringe, and/or split-pack or other suitable container). In some embodiments, the provided kits may optionally further comprise a second container comprising a pharmaceutically acceptable excipient for diluting or suspending a pharmaceutical composition or compound described herein. In some embodiments, the pharmaceutical compositions or compounds described herein disposed in the first and second containers are combined to form one unit dosage form.
In certain embodiments, the kits described herein further comprise instructions for using the compounds or pharmaceutical compositions contained in the kit. The kits described herein may also include information required by regulatory agencies such as the U.S. Food and Drug Administration (FDA). In certain embodiments, the information included in the kit is prescription information. In certain embodiments, the kits and instructions provide for the treatment and/or prevention of a proliferative disease in a subject in need thereof. The kits described herein may comprise one or more additional pharmaceutical agents as separate compositions.
The present invention is described in further detail below with reference to specific examples, but the present invention is not limited to the following examples, which are intended to better illustrate certain embodiments of the present invention and should not be construed as limiting the scope of the present invention in any way. Conditions not noted in the examples are conventional conditions. Unless otherwise specified, reagents and equipment used in the following examples are commercially available products.
The structures of the compounds in the following examples were determined by Nuclear Magnetic Resonance (NMR) or/and Mass Spectrometry (MS). NMR shifts (. delta.) are given in units of 10-6 (ppm). NMR was measured using a Bruker AVANCE-400 NMR spectrometer using deuterated dimethylsulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD) and Tetramethylsilane (TMS) as an internal standard.
MS was determined using a FINNIGAN LCQAD (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX).
The thin layer chromatography silica gel plate is HSGF254 of tobacco yellow sea or GF254 of Qingdao, the specification of silica gel plate used by Thin Layer Chromatography (TLC) is 0.15mm-0.2mm, and the specification of thin layer chromatography separation and purification product is 0.4mm-0.5 mm.
The column chromatography generally uses 200-mesh and 300-mesh silica gel of the Tibet yellow sea silica gel as a carrier.
In the examples, the reaction temperature is, unless otherwise specified, room temperature and is 20 ℃ to 30 ℃.
The reaction progress in the examples was checked by Thin Layer Chromatography (TLC), the developing solvent system used, and the elution system for column chromatography used for purifying the compounds included: a: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether and ethyl acetate system, D: acetone and petroleum ether system, the volume ratio of the solvent is adjusted according to the polarity of the compound.
Abbreviations used in the experiments: NCS, N-chlorosuccinimide; PdCl2(dtbpf), dichloro [1,1' -bis (oto-tert-butylphosphino) ferrocene palladium (II); boc, tert-butoxycarbonyl; THF, tetrahydrofuran; EA, ethyl acetate; DCM, dichloromethane; DIPEA, diisopropylethylamine; DMF, N-dimethylamide; TFA, trifluoroacetic acid; h, hours; TEA, triethylamine.
Example 1: preparation of Compound 1
Compound 1 was prepared according to the following route using starting material 1-1.
Step 1: synthesis of intermediate 1-2
The starting materials 1-1(4.0g, 0.017mol), NCS (2.5g, 0.018mol) were dissolved in DMF (40ml) and reacted overnight at 70 ℃. After the reaction, the reaction mixture was poured into 100mL of ice-water and filtered with suction to obtain a solid (4.6 g).
MS m/z(ESI):269.9[M+1].
Step 2: synthesis of intermediates 1 to 3
Compound 1-2(4.6g, 0.017mol) was dissolved in ethanol (60ml), formamidine acetate (21.4g, 0.20mmol) was added, and the reaction was heated under reflux overnight. After completion of the reaction, the dry ethanol was concentrated, 20ml of water and 60ml of EA were added for liquid separation, and the concentrated organic phase was dried to obtain a crude solid (5.2g) which was used directly in the next step.
MS m/z(ESI):276.9[M+1].
And step 3: synthesis of intermediates 1 to 4
Compound 1-3(5.2g, 0.018mol) was added to SOCl2To (30mL) was added dropwise 6 drops of DMF, and the mixture was refluxed overnight. After completion of the reaction, the dry SOCl was concentrated2Then, saturated sodium bicarbonate and EA were added to separate the solution, and the organic phase was concentrated by drying and purified by column chromatography to obtain a yellow solid (3.0g).
And 4, step 4: synthesis of intermediates 1 to 6
Compound 1-4(296mg, 1.0mmol) and compound 1-5(400mg, 2.0mmol) were dissolved in dioxane (6ml), DIPEA (387mg, 3.0mmol) was added, and the mixture was heated to 50 ℃ to react. After the reaction is finished, H is added2O (5ml) and EA (15ml), extracting to obtain an organic phase, drying and concentrating the organic phase, and purifying by column chromatography to obtain a solid (300 mg).
MS m/z(ESI):459.0[M+1].
And 5: synthesis of intermediates 1 to 8
Compounds 1-6(200mg, 0.43mmol) were dissolved in dioxane/H2O (6ml/2ml), boric acid 1-7(163mg, 0.52mmol, see WO2020081282 synthesis) and PdCl2(dtbpf)(28.4mg,0.04mmol,0.1eq),K3PO4(139mg,0.65mmol),N2Heating to 90 ℃ under protection and reacting for 2 h. After the reaction was completed, 5ml of water and 15ml of EA were added, and the organic phase was extracted, dried, concentrated, and purified to obtain a solid (78 mg).
MS m/z(ESI):647.2[M+1].
Step 6: synthesis of intermediates 1 to 9
Compound 1-8(78mg) was dissolved in DCM (6ml), and 1ml TFA was added to the mixture, and the mixture was reacted at room temperature overnight, after completion of the reaction, the reaction mixture was concentrated to dryness, EA was added, the pH was adjusted to about 8 with saturated sodium bicarbonate, and the organic phase was dried and concentrated to obtain a crude product (70.0 mg).
And 7: synthesis of Compound 1
Compounds 1-9(70.0mg, 0.156mmol) were dissolved in THF/H2To O (2ml/2ml), K was added2CO3(95.3mg,0.69mmol),N2Cooled to 0 ℃ under protection, acryloyl chloride (14.2mg, 0.156mmol) was slowly added dropwise, and the reaction was continued for 10min at 0 ℃ after the addition. After the reaction is finished, addingAdding water, extracting with EA, drying the organic phase, concentrating, and purifying by column chromatography to obtain white solid (30.0 mg).
1H NMR(400MHz,CDCl3):8.80(s,1H),7.77(s,1H),7.24-7.22(m,1H),7.02-6.97(m,1H),6.65-6.56(m,1H),6.40-6.37(m,1H),5.80-5.76(m,3H),4.76-4.65(m,1H),4.20-4.04(m,2H),3.73-3.46(m,4H),1.42-1.40(m,3H).
MS m/z(ESI):501.1[M+1].
The following compounds of examples 2-4 were prepared using a synthetic route analogous to that described in example 1, substituting only the starting piperazine 1-5 involved. Example numbers, compound designations and structural characterizations are listed in the following table:
example 5: preparation of Compound 5
Compound 1 was prepared according to the following route using starting materials 5-6.
Step 1: synthesis of intermediates 5 to 7
Compound 5-6(500mg, 1.12mmol) was dissolved in DMSO (10ml), and added to 25% aqueous ammonia (160mg) in a sealed tube and heated to 90 ℃ for reaction overnight. After the reaction was completed, 5ml of water and 15ml of EA were added, and the organic phase was extracted, dried, concentrated, and purified to obtain intermediate 5-7(105 mg).
1H NMR(400MHz,CDCl3):8.62(s,1H),7.26(s,1H),5.57(brs,2H),3.70-3.64(m,8H),1.50(s,3H);MS m/z(ESI):442.1[M+1].
Step 2: synthesis of intermediates 5 to 8
Dissolve compound 5-7(55mg, 0.12mmol) in dioxane/H2O(3ml/1ml), boric acid 1-7(60mg, 0.19mmol) and PdCl are added2(dtbpf)(8.2mg,0.012mmol),K3PO4(40mg,0.18mmol),N2Heating to 90 ℃ under protection and reacting for 2 h. After the reaction was completed, 5ml of water and 15ml of EA were added, and the organic phase was extracted, dried, concentrated, and purified to obtain intermediate 5-8(17 mg).
MS m/z(ESI):630.3[M+1].
And step 3: synthesis of intermediates 5 to 9
Compound 5-8(30mg) was dissolved in DCM (2ml), 0.5ml TFA was added, the reaction was allowed to proceed overnight at room temperature, after completion of the reaction, the reaction mixture was concentrated to dryness, EA was added, the pH was adjusted to about 8 with saturated sodium bicarbonate, and the organic phase was dried and concentrated to obtain a crude product (28 mg).
And 4, step 4: synthesis of Compound 5
Compound 5-9(28mg, 0.069mmol) was dissolved in THF/H2To O (2ml/2ml), K was added2CO3(42.5mg,3.08mmol),N2Cooled to 0 ℃ under protection, acryloyl chloride (6.9mg, 0.083mmol) is slowly added dropwise, and the reaction is continued for 10min at 0 ℃ after the addition. After the reaction, water was added, and EA was used for extraction, and the organic phase was dried, concentrated, and purified by column chromatography to obtain a white solid (12.5 mg).
MS m/z(ESI):484.1[M+1].
The following compounds of examples 6-8 were prepared using a synthetic route analogous to that described in example 2, substituting only a portion of the starting materials involved. Example numbers, compound designations and structural characterizations are listed in the following table:
test example 1: evaluation of Compounds for modification of KRAS-G12C
Purpose of the experiment:
this example illustrates covalent binding of an exemplary compound of the invention to KRAS G12C and determination of the covalent adduct of a compound of the invention with KRAS G12C using LCMS
The experimental steps are as follows:
1. loading GDP onto KRAS-4B-G12C protein
1) KRAS-4B-G12C protein was diluted one-fold with low magnesium buffer to a concentration of 103 uM.
2) To 1mL of 103uM KRAS-4B-G12C protein was added 1mL of 2X GDP loading buffer, and gently and slowly mixed.
3) 2mL of the mixture was reacted at room temperature for 1.5 h.
4) Subpackaging into 100 uL/tube, quickly freezing with liquid nitrogen, and storing at-80 deg.C.
2. Covalent modification analysis of KRAS-4B-G12C protein by small molecule compound
1) KRAS-4B-G12C protein was diluted with 10 Xreaction buffer to prepare a reaction system as shown in the following table:
2) the reaction was carried out at room temperature for 3min and 30min, respectively.
3) The reaction was stopped by adding 5uL of 5% formic acid.
3. Mass spectrometric detection
A total of 55uL of the reaction was centrifuged at 15000rpm for 10min before mass spectrometric detection.
4. The coupling ratio to Kras-G12C was calculated
Coupling ratio (%). protein-compound complex peak area/(complex peak area + monomer protein peak area). 100.
The mass of each protein was calculated as a percentage of the total signal of that protein, which was then normalized to the signal of the protein without the addition of reactive compound. These normalized signals are reported as normalized control Percentage (POC). An increase in POC values indicates that the compound shows a higher degree of modification of KRASG 12C. The results of testing the exemplary compounds of formula (I) at a concentration of 3. mu.M for 30 minutes are shown in Table 2.
Specific test data are shown in table 1 below.
Compound (I) | POC | Compound (I) | POC | Compound (I) | POC | Compound (I) | POC | Compound (I) | POC |
1 | 89.8% | 2 | 75.5% | 3 | 71.5% | 4 | 60.5% | B | 55.2% |
And (4) conclusion: the compounds of the invention all showed better KRASG12C covalent binding capacity than control compound B.
Test example 2: compounds for KRAS G12C mutant cell Activity assay
This experiment was conducted to verify the inhibition of ERK phosphorylation in KRAS G12C mutant NCI-H358 human non-small cell lung cancer cells by the compounds of the invention.
The main reagents are as follows:
cell line NCI-H358, RPMI1640 culture medium, FBS, TrypLETMExpress Enzyme, PBS, 8% fixative, blocking solution, 100% methanol, rabbit anti-pERK, mouse anti-GAPDH, IRDye 800CW goat anti-rabbit IgG, IRDye680RD goat anti-mouse IgG
Main consumables and instrument:
t75 cell culture bottle, 384 cell culture micro-plate, CO2Constant temperature incubator, Eppendorf centrifuge, Echo 550 liquid workstation, infrared laser imaging system Odyssey CLx
The experimental method comprises the following steps:
4 x 106NCI-H358 cells (purchased from ATCC) were inoculated into T75 flasks, cultured for 2 days at 37 degrees, 5% CO with RPMI1640 (both purchased from Gibco) supplemented with 10% FBS (purchased from Transgene) and 1% penicillin streptomycin2. On day 3, the medium was decanted and washed once with DPBS. Adding 2ml TrypLETMExpress Enzyme (from Gibco) was digested at room temperature until the cells became round. 5ml of fresh medium was added, the cells were aspirated and collected. Centrifuge at 1000rpm for 5 minutes. The supernatant was discarded, and the cells were resuspended in fresh medium and counted. Mu.l of 6000 cells per well in 384-well plates, 37 ℃ in 5% CO2The culture was carried out overnight. The next day, 200nl per well of gradient diluted compound (0.5% DMSO, starting concentration 1000nm,3 fold dilution, 10 concentration points) was added with Echo 550 and incubation was continued for 3 hours. Add 40. mu.l of 8% fixative (from Solarbio) to each well and incubate for 20 min at room temperature. Add 40 u l PBS washing once. Then 40. mu.l of 100% cold methanol was added and incubated for 10 minutes at room temperature. Wash once with 40. mu.l PBS. Mu.l of blocking solution (purchased from Licor) was added to each well and incubated for 1 hour at room temperature. The blocking solution was aspirated and 20 μ l of primary antibody cocktail, rabbit anti-pERK (purchased from CST, 1:1000 dilution) and mouse anti-GAPDH (purchased from CST, 1:2000 dilution), 4 degrees overnight. 40 μ l each well of PBST containing 0.05% Tween was washed 3 times. Mu.l of secondary antibody mixture, IRDye 800CW goat anti-rabbit IgG and IRDye680RD goat anti-mouse IgG (both purchased from Li-COR, both diluted 1: 2000) were added to each well and incubated for 45 minutes at room temperature. Add 40. mu.l PBST per well and wash 3 times. The plates were centrifuged at 1000rpm for 1 minute and the plates were read with an Odyssey CLx.
And (3) data analysis: IC (integrated circuit)50Results were analyzed by GraphPad Prism 5.0 software.
Specific test data are shown in table 2 below.
And (4) conclusion: the compounds of the present invention all showed stronger inhibitory activity than control compound a and control compound B.
Test example 3: evaluation of activity of compounds on cells for experimental purposes:
this experiment was conducted to verify the inhibition of KRAS G12C mutant NCI-H358 human non-small cell lung cancer cell proliferation by the compounds of the present invention.
The main reagents are as follows:
cell line NCI-H358, RPMI1640 culture medium, FBS, TrypLETMExpress Enzyme, PBS, CellTiter-Glo 3D Cell Viability Assay kit main consumables and instruments:
t75 cell culture bottle, 384 ultra-low adhesion cell culture round bottom micro-porous plate, CO2The experimental method comprises the following steps of (1) a constant-temperature incubator, an Eppendorf centrifuge, an Echo 550 liquid workstation and an Envision multi-label analyzer:
200nl of a gradient dilution compound (starting concentration 1000nM,3 fold dilution, 10 concentration points) was added to 384 ultra low adhesion cell culture round bottom microplates and 40. mu.l of 800 freshly digested NCI-H358 cells in logarithmic growth phase, 37 ℃ 5% CO was seeded2The culture was carried out for 3 days in RPMI1640 supplemented with 10% FBS and 1% penicillin streptomycin. On day 4, 20. mu.l of CellTiter-Glo 3D Cell Viability reagent (from Promega) was added, shaken at room temperature for 1 hour, and then read with an Envision multi-label analyzer。
And (3) data analysis: IC50 results were analyzed by GraphPad Prism 5.0 software.
Specific test data are shown in table 3 below.
And (4) conclusion: most of the compounds of the present invention unexpectedly show stronger cellular tumor inhibiting activity than control compound a and control compound B.
Test example 4: stability test of Compounds in Whole blood of mice
This experiment was conducted to examine the stability of the compounds of the present invention in whole blood samples from mice.
Samples (n-3) were prepared at room temperature using ICR male EDTA-K2 whole blood as a blank medium at 100 ng/mL. A stability sample is taken out at a predetermined time point (for example, immediately after preparation, 1 hour), and centrifuged (centrifugation conditions: 1500. + -.20 g, temperature: 2 to 8 ℃ C., centrifugation 10min) to obtain a plasma sample.
Adding the plasma sample into an internal standard solution, performing vortex for about 1min, 15400g and 4 ℃, centrifuging for 10min, taking supernate, performing sample injection analysis, calculating a result according to the peak area ratio of an analyte to the internal standard, comparing the ratio of the response average peak area of the stability sample at each time point with the prepared immediate sample, wherein the deviation of the measured value of the stability sample and the prepared immediate sample is not more than +/-15.0%. The 1h stability results are shown in table 4 below.
Compound (I) | Deviation of | Compound (I) | Deviation of | Compound (I) | Deviation of | Compound (I) | Deviation of | Compound (I) | Deviation of |
1 | -1.33% | 2 | -12.8% | 3 | +14.0% | 4 | +9.4% | B | -27.1% |
And (4) conclusion: the compounds of the invention unexpectedly show better stability in whole mouse blood compared to the disclosed comparative compound B.
Test example 5: stability test of Compounds in human Whole blood
This experiment was intended to investigate the stability of the compounds of the invention in human whole blood samples.
Samples (n-3) were prepared at room temperature using human whole blood as a blank medium at a concentration of 100 ng/mL. A stability sample is taken out at a predetermined time point (for example, immediately after preparation, 1 hour), and centrifuged (centrifugation conditions: 1500. + -.20 g, temperature: 2 to 8 ℃ C., centrifugation 10min) to obtain a plasma sample.
Adding the plasma sample into an internal standard solution, performing vortex for about 1min, 15400g and 4 ℃, centrifuging for 10min, taking supernate, performing sample injection analysis, calculating a result according to the peak area ratio of an analyte to the internal standard, comparing the ratio of the response average peak area of the stability sample at each time point with the prepared immediate sample, wherein the deviation of the measured value of the stability sample and the prepared immediate sample is not more than +/-15.0%. The 1h stability results are shown in table 5 below.
Compound (I) | Deviation of | Compound (I) | Deviation of | Compound (I) | Deviation of |
3 | +3.2% | 4 | +5.8% | B | -35.4% |
And (4) conclusion: the compounds of the present invention unexpectedly show better stability in human whole blood compared to the disclosed comparative compound B.
Test example 6: evaluation of pharmacokinetics:
the drug concentrations in plasma of mice at different times after intragastric administration of compound 1, compound 3 and compound B were tested using the mice as test animals. The pharmacokinetic behavior of the compound of the invention in mice is studied, and the drug metabolism characteristics are evaluated. In each group of examples, 9 mice of similar body weight were used, and the oral administration dose was 10mg/kg, and the administration was a single dose. Blood was collected at 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h, 24h time points after administration to the animals (2 time point samples per mouse for 3 time points). The content of the compound in the plasma is detected by adopting an LC-MS/MS analysis method, and the lower limit of the quantification of the method is 20 ng/mL. The plasma concentration data were statistically analyzed using the pharmacokinetic data analysis software WinNonlin 7.0, and the pharmacokinetic parameters were calculated using the non-compartmental model (NCA), as shown in table 2 below.
The experimental scheme is as follows:
experimental drugs: compound 1, compound 3, compound B.
The preparation of the medicine comprises the following steps: a certain amount of the medicine is taken, and 2% Klucel LF + 0.1% Tween 80 aqueous solution is added to prepare a clear solution or a uniform suspension.
Administration: the mice were fasted overnight and then gavaged at a dose of 10 mg/kg.
The operation is as follows: the mouse is administrated by gastric lavage, tail vein blood is collected before administration and 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h and 24h after administration, the blood plasma is separated by centrifugation for 10 minutes at 3500 rpm at 4 ℃ in a heparinized sample tube, the blood plasma is stored at-20 ℃, and the mouse is taken 2 hours after administration.
Determining the content of the compound to be tested in the plasma of the mouse after the drug with different concentrations is administered by gavage: after thawing the plasma samples at room temperature, respectively taking 50 mu L, adding 130 mu L of internal standard working solution (1000ng/mL, acetonitrile, tolbutamide), vortexing for about 1min, and centrifuging for 10min at 4 ℃ and 13000 rpm. mu.L of the supernatant was mixed with 100. mu.L of 50% acetonitrile water and analyzed by LC/MS/MS.
The pharmacokinetic parameter results are shown in table 6.
Table 4: drug metabolism data in mice
And (4) conclusion: the compound of the invention has good drug absorption, especially the compound 3, compared with the control compound B, not only greatly prolongs the half-life period, but also greatly improves the drug exposure in blood.
The above embodiments are merely illustrative of the technical ideas and features of the present invention, and the purpose thereof is to enable those skilled in the art to understand the contents of the present invention and implement the present invention, and not to limit the protection scope of the present invention. All equivalent changes and modifications made according to the spirit of the present invention should be covered within the protection scope of the present invention.
Claims (10)
1. A compound represented by the following formula (I) and isomers thereof or pharmaceutically acceptable salts thereof,
wherein the content of the first and second substances,
R1is selected from-H, -CH3、-CH2CN;
R2Is selected from-H, -CH3;
R3Is selected from-H, -CH3;
R4Selected from-F, -NH2、-NHCH3;
When R is4When is-F, said R1、R2、R3Cannot be simultaneously-H.
2. The compound of formula (I) and isomers or pharmaceutically acceptable salts thereof according to claim 1, wherein R is1is-CH2CN;R2is-H; r3is-H; r4Selected from-F, -NH2。
3. The compound of formula (I) and isomers or pharmaceutically acceptable salts thereof according to claim 1, wherein R is1is-H; r2is-CH3;R3is-H; r4Selected from-F, -NH2。
4. The compound of formula (I) and isomers or pharmaceutically acceptable salts thereof according to claim 1, wherein R is1is-H; r2is-CH3;R3is-CH3;R4Selected from-F, -NH2。
5. The compound of formula (I) and isomers or pharmaceutically acceptable salts thereof according to claim 1, wherein R is1is-CH3;R2is-H; r3is-H; r4Selected from-F, -NH2。
6. The compound represented by the formula (I) and isomers thereof or pharmaceutically acceptable salts thereof according to any one of claims 1 to 5, wherein R is4is-F.
8. use of a compound represented by formula (I) according to any one of claims 1 to 7, and isomers thereof or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of KRASG12C mutein-related cancer selected from the group consisting of: lung cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, esophageal cancer, bile duct cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, brain glioma, lymphoma, and leukemia.
9. A pharmaceutical composition for treating KRASG12C mutein-related cancer comprising a therapeutically effective amount of a compound represented by formula (I) according to any one of claims 1 to 7 and pharmaceutically acceptable salts and isomers or pharmaceutically acceptable salts thereof as an active ingredient, together with pharmaceutically acceptable excipients, said KRASG12C mutein-related cancer disease being selected from the group consisting of: lung cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, esophageal cancer, bile duct cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, brain glioma, lymphoma, and leukemia.
10. A method of treating KRASG12C mutant protein-associated cancer, the method comprising administering to a subject an effective amount of a compound represented by formula (I) and pharmaceutically acceptable salts and isomers thereof or pharmaceutically acceptable salts thereof according to any one of claims 1 to 7 as an active ingredient in a pharmaceutical composition, wherein the KRASG12C mutant protein-associated cancer disease is selected from the group consisting of: lung cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, esophageal cancer, bile duct cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, brain glioma, lymphoma, and leukemia.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010636659.1A CN113880827A (en) | 2020-07-03 | 2020-07-03 | Compound for inhibiting KRASG12C mutant protein and preparation method and application thereof |
PCT/CN2021/102995 WO2022002018A1 (en) | 2020-07-03 | 2021-06-29 | Compound for inhibiting krasg12c mutant protein, preparation method therefor, and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010636659.1A CN113880827A (en) | 2020-07-03 | 2020-07-03 | Compound for inhibiting KRASG12C mutant protein and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113880827A true CN113880827A (en) | 2022-01-04 |
Family
ID=79013292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010636659.1A Pending CN113880827A (en) | 2020-07-03 | 2020-07-03 | Compound for inhibiting KRASG12C mutant protein and preparation method and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113880827A (en) |
WO (1) | WO2022002018A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4294799A2 (en) * | 2021-02-16 | 2023-12-27 | Theras Inc. | Compositions and methods for inhibition of ras |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
US20240043451A1 (en) * | 2022-03-25 | 2024-02-08 | Eli Lilly And Company | Kras inhibitors |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200115375A1 (en) * | 2018-10-15 | 2020-04-16 | Eli Lilly And Company | Kras g12c inhibitors |
CN113754653A (en) * | 2020-06-05 | 2021-12-07 | 明慧医药(上海)有限公司 | KRAS G12C inhibitor compound and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106488910B (en) * | 2013-10-10 | 2020-07-31 | 亚瑞克西斯制药公司 | Inhibitors of KRAS G12C |
CN111630053A (en) * | 2018-01-19 | 2020-09-04 | 南京明德新药研发有限公司 | Pyridinopyrimidine derivatives as KRASG12C mutant protein inhibitors |
-
2020
- 2020-07-03 CN CN202010636659.1A patent/CN113880827A/en active Pending
-
2021
- 2021-06-29 WO PCT/CN2021/102995 patent/WO2022002018A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200115375A1 (en) * | 2018-10-15 | 2020-04-16 | Eli Lilly And Company | Kras g12c inhibitors |
CN113754653A (en) * | 2020-06-05 | 2021-12-07 | 明慧医药(上海)有限公司 | KRAS G12C inhibitor compound and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2022002018A1 (en) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113880827A (en) | Compound for inhibiting KRASG12C mutant protein and preparation method and application thereof | |
CN112390788A (en) | Compound for inhibiting KRASG12C mutant protein and preparation method and application thereof | |
EP2906563B1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
CN114195788A (en) | Tetracyclic compound and application thereof | |
EP4077326A1 (en) | Kras mutant protein inhibitors | |
CN112608318B (en) | Compound as protein kinase inhibitor and application thereof | |
WO2021218110A1 (en) | Benzothiazolyl biaryl compound, and preparation method and use | |
US11192900B2 (en) | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors | |
JP6407955B2 (en) | Coumarin derivatives and methods of use in treating hyperproliferative diseases | |
CA3090330A1 (en) | Atr inhibitor and application thereof | |
EP3684772B1 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
BR112019012300A2 (en) | nrf2 activators | |
CN107428762B (en) | Phthalazinone derivatives, preparation method and use thereof | |
CN112805287B (en) | BTK inhibitors containing furo [3,4-b ] pyrroles | |
CN112243437A (en) | Acryloyl group-containing nuclear transport modulators and uses thereof | |
WO2023215803A2 (en) | Cytochrome bd oxidase inhibitors and uses thereof | |
CN113416181B (en) | Quinazoline derivative and application thereof | |
JP2022053557A (en) | Pyridone derivative | |
CN112851667B (en) | Nitrogen-containing heterocyclic ring compound and medicinal composition and application thereof | |
CN114539246A (en) | Piperidinopyrimidine compound and application thereof | |
CN114409653A (en) | Bridged ring pyrimidine-fused ring compound and application thereof | |
CN114907387B (en) | Pyrimido pyrrole KRAS inhibitor and preparation method and application thereof | |
RU2803116C2 (en) | Quinolinil-containing compound, its pharmaceutical composition and use | |
CN111233837A (en) | Thiosemicarbazone compound and preparation method and application thereof | |
EA037384B1 (en) | Protein kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |